CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Solifenacin succinate

Last Updated: January 5, 2009
Result type: Reports
Project Number: SR0155-000
Product Line: Reimbursement Review

Generic Name: Solifenacin succinate

Brand Name: Vesicare

Manufacturer: Astellas Pharma Canada Inc.

Therapeutic Area: Bladder, overactive

Indications: Bladder, overactive

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: June 17, 2009

Recommendation Type: List with clinical criteria and/or conditions